Intimation of the Annual General Meeting to be held on 17th September, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Evoq Remedies Limited has called its 15th AGM for Wednesday, 17th September 2025 at 4:00 PM, to be held via video conferencing. Ordinary business includes adoption of the FY2024-25 audited financial statements and re-appointment of Managing Director Bhumishth Patel (DIN: 02516641), who retires by rotation. Shareholders will also vote on appointing M/s. H Thakkar & Co. LLP, Chartered Accountants, as statutory auditor for a 5-year term, from the conclusion of the 15th AGM until the 19th AGM in 2029. The special business section seeks approval for material related party transactions with eight separate entities — Poshan Nutriwell, Solaris Agritech, Recurso Wellness, EL Faro Ventures, Vogue Lifestyle, Patron Exim, Solis Inventions, and Atlantis Exim — each with an aggregate cap of Rs. 50 crore, taking the combined potential RPT exposure to up to Rs. 400 crore. The book closure window runs from 10th to 17th September 2025, with the cut-off date for e-voting set as 10th September 2025.
For retail shareholders, the AGM agenda is largely routine — financial adoption, director re-appointment, and auditor appointment. However, the unusually large number of related party transaction approvals (eight entities, up to Rs. 50 crore each) is worth close attention, as it significantly expands the company's ability to transact with related parties over the coming year. Investors may want to scrutinise the rationale and pricing of these RPTs, as they can be a governance red flag if not conducted at arm's length.